Android app on Google Play

Merriman Curhan Ford Initiates Coverage on Facet Biotech (FACT) with a Buy

September 28, 2009 7:26 AM EDT Send to a Friend
Get Alerts FACT Hot Sheet
Price: $27.01 --0%

Rating Summary:
    0 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 22 | New: 12
Trade FACT Now!
Join SI Premium – FREE
Merriman Curhan Ford initiates coverage on Facet Biotech (Nasdaq: FACT) with a Buy rating.

Merriman analyst says, "Facet Biotech represents a unique investment opportunity in the biotech space, combining a modest enterprise value, a late-stage clinical asset with a high probability of success, a robust development-stage pipeline, and an experienced management and board team with a desire and ability to succeed. The combination of modest valuation juxtaposed against latestage development increases the odds of success for investors. Facet was off the Street’s radar screen until the recent unsolicited bid from Biogen, which puts a floor of valuation under the shares in the $14-15 range."

To see more analyst ratings on FACT Click Here.




You May Also Be Interested In


Related Categories

New Coverage

Related Entities

Merriman Curhan Ford

Add Your Comment